Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 16/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | DRD2 | P14416 | 9/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30231809 | 1.00 | DRD1 (1.00) | DRD1KDM4EMAPTPMP22TSHR | |
| SCHEMBL30026797 | 1.00 | DRD1 (1.00) | DRD1KDM4EMAPTPMP22TSHR | |
| Bromide SCHEMBL29634914 | 0.99 | DRD1 (1.00) | DRD1KDM4EMAPTPMP22TSHR | |
| Bromide SCHEMBL12610614 | 0.99 | DRD1 (1.00) | DRD1KDM4EMAPTPMP22TSHR | |
| SCHEMBL14510734 | 0.90 | DRD1 (0.81) | DRD1KDM4EMAPTPMP22TSHR | |
| SCHEMBL7323497 | 0.88 | DRD1 (1.00) | DRD1KDM4EMAPTPMP22TSHR | |
| Bromide SCHEMBL29634894 | 0.87 | DRD1 (1.00) | DRD1KDM4EMAPTPMP22TSHR | |
| Bromide SCHEMBL7320300 | 0.87 | DRD1 (1.00) | DRD1KDM4EMAPTPMP22TSHR | |
| SCHEMBL34464664 | 0.87 | DRD1 (0.80) | DRD1KDM4EMAPTPMP22TSHR | |
| SCHEMBL14495044 | 0.84 | DRD1 (0.72) | DRD1KDM4EMAPTPMP22TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4523686-A1 | A SIGMA-1 RECEPTOR POSITIVE MODULATOR FOR ITS USE IN THE PREVENTION AND THE TREATMENT OF A PATHOLOGY | UNIVERSITE DE MONTPELLIER (FR) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023006412-A1 | SIGMA-1 RECEPTOR ACTIVATOR FOR USE IN THE TREATMENT OF A PATHOLOGY ASSOCIATED WITH WFS1 MUTATION | UNIVERSITÉ DE MONTPELLIER (FR) | 2023-02-02 | — | — | WO | disclosed |
| EP-4124338-A1 | SIGMA-1 RECEPTOR ACTIVATOR FOR USE IN THE TREATMENT OF A PATHOLOGY ASSOCIATED WITH WFS1 MUTATION | Université de Montpellier (FR) | 2023-02-01 | — | — | EP | disclosed |
| US-20200164068-A1 | MODULATORS OF TUMOR IMMUNE RESISTANCE FOR THE TREATMENT OF CANCER | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2020-05-28 | — | — | US | disclosed |
| US-20190054110-A1 | MODULATORS OF CCR9 FOR TREATING TUMOR RESISTANCE TO IMMUNE RESPONSES | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2019-02-21 | — | — | US | disclosed |
| EP-3416641-A1 | MODULATORS OF CCR9 FOR TREATING TUMOR RESISTANCE TO IMMUNE RESPONSES | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts (DE) | 2018-12-26 | — | — | EP | disclosed |
| EP-3416640-A1 | MODULATORS OF TUMOR IMMUNE RESISTANCE FOR THE TREATMENT OF CANCER | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts (DE) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017140803-A1 | MODULATORS OF TUMOR IMMUNE RESISTANCE FOR THE TREATMENT OF CANCER | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140793-A1 | MODULATORS OF CCR9 FOR TREATING TUMOR RESISTANCE TO IMMUNE RESPONSES | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2017-08-24 | — | — | WO | disclosed |
| US-9593360-B2 | Measurement of brain CDP-diacylglycerol synthase 1 enzyme and uses thereof | UNDIEH ASHIWEL S (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160317474-A1 | Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects | UNIV EMORY (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015095257-A2 | MANAGING VISUAL DYSFUNCTION OR LOSS OF VISION FOR DIABETIC SUBJECTS | EMORY UNIVERSITY (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20130022978-A1 | Measurement of Brain CDP-Diacylglycerol Synthase 1 Enzyme and Uses Thereof | UNDIEH ASHIWEL S (US) | 2013-01-24 | — | — | US | disclosed |
| US-8278296-B2 | Manipulation of brain CDP-diacylglycerol and uses thereof | UNDIEH ASHIWEL S (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100311728-A1 | Manipulation of brain CDP-diacylglycerol and uses thereof | UNDIEH ASHIWEL S | 2010-12-09 | — | — | US | disclosed |
| US-7763603-B2 | Manipulation of brain CDP-diacylglycerol and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-27 | — | — | US | disclosed |
| US-20080039443-A1 | Manipulation of brain CDP-diacylglycerol and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-02-14 | — | — | US | disclosed |
| US-20070142399-A1 | Dual function drugs and uses thereof | PSYCHIATRIC GENOMICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142399-A1 | Dual function drugs and uses thereof | PSYCHIATRIC GENOMICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142399-A1 | Dual function drugs and uses thereof | COMT, DRD2, SLC6A3 | DRD1 6/4885KDM4E 3362/4885MAPT 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.